# EQT Life Sciences

> EQT Life Sciences is a VC fund backing Biotechnology and Health Care. See 184 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Amsterdam, The Netherlands
- Total investments: 184
- Last investment: Jul 2026
- Lead investor: 41%
- Fund size: $266M
- Last fund: Mar 2023
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/lspvc/
- X (Twitter): https://twitter.com/LSP_PublicFund
- Website: https://lspvc.com/

EQT Life Sciences is a VC fund in Amsterdam focused on Biotechnology and Health Care. EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.

## Contacts

5 contacts available for EQT Life Sciences. Shizune tracks 12 team members at EQT Life Sciences. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/life-sciences-partners?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $7.3M–$78M |
| Series B | $12M–$110M |
| Series C | $12M–$165M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 81 | 44% |
| Health Care | 69 | 38% |
| Therapeutics | 41 | 22% |
| Medical | 34 | 18% |
| Medical Device | 25 | 14% |

34 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 44 | 24% |
| Series B | 43 | 23% |
| Series C | 25 | 14% |
| Funding Round | 12 | 7% |
| Series D | 11 | 6% |

12 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 32 | 17% |
| The Netherlands | 14 | 8% |
| Switzerland | 13 | 7% |
| Germany | 11 | 6% |
| Belgium | 8 | 4% |

14 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Christoph Broja | Partner | 2 | https://shizune.co/investors/profile/christoph-broja-c9a3 |
| Fouad Azzam | General Partner | 16 | https://shizune.co/investors/profile/fouad-azzam |
| Joachim Rothe | General Partner | 14 | https://shizune.co/investors/profile/joachim-rothe |
| Daniela Begolo | Managing Director | 3 | https://shizune.co/investors/profile/daniela-begolo |
| Ellen Cordo | Chief Finance | 0 | https://shizune.co/investors/profile/ellen-cordo |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Xeltis | A clinical-stage medical device company, Xeltis has developed the most advanced polymer-based restorative devices for cardiovascular treatment. Xeltis’ restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and for coronary artery bypass graft (CABG) surgery and pulmonary heart valves, for whichclinical trials are ongoing. Xeltis was formed through the merger of two Dutch/Swiss university spin-offs. It currently has operations in The Netherlands and in the USA. Xeltis’ investors include venture capital funds EQT Life Sciences, Kurma Partners, VI Partners and Ysios Capital as well as a number of private investors. In 2021, Xeltis secured a €15 million financing from the European Investment Bank and a €15 million funding from the European Innovation Council Accelerator (EIC) set up by the European Commission. | $23.3M | Venture - Series Unknown | Jul 28, 2026 |  |
| RQ Bio | RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza with the goal of providing immediate, powerful, and long-lasting protection against severe viral disease in immunocompromised and high-risk subjects. The company's mission is to deliver "instant immunity" through passiveimmunization, helping protect vulnerable populations such as the elderly, newborns, and immunocompromised patients from severe infectious diseases. The company specializes in the discovery and development of broad-spectrum antiviral antibodies that are engineered to remain effective even as viruses evolve. Its scientific approach combines virology, antibody engineering, computational biology, and immune-directed discovery techniques to identify potent antibodies that target conserved regions of viral proteins, reducing the risk of resistance caused by viral mutations.RQ Bio's lead programs focus on infectious diseases such as influenza, COVID-19, respiratory syncytial virus (RSV), and cytomegalovirus (CMV). The company is currently developing long-acting monoclonal antibodies designed to provide once-yearly protection against seasonal influenza, particularly for individuals at high risk of severe disease. | $112.5M | Series A | Jun 24, 2026 |  |
| Onward | Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI). | $47.8M | Post-IPO Equity | Apr 16, 2026 |  |
| Neurent Medical | Neurent Medical is a medical device startup that develops non-surgical treatments for inflammatory sino-nasal diseases. It was founded in 2015 by Brian Shields and David Townley in Oranmore, Galway, Ireland. | $74.5M | Series C | Feb 11, 2026 |  |
| Tenpoint Therapeutics | Tenpoint Therapeutics is a biotechnology company pursuing vision-restoring engineered cell-based therapeutics. | $85M | Series B | Jan 28, 2026 |  |
| Exciva | exciva is a Provider of targeted drug rescue program intended to involve pharmaceutical research and development based in Heidelberg, Germany. The company's program has been formulated for developing symptomatic and disease-modifying treatments, therapies, cures, prophylactics, supplements, formulations and methods of making and using suchcompositions, enabling the healthcare industry to access their program for rescuing and reusing approved drugs for new indications and new uses. | $62.2M | Series B | Jan 20, 2026 |  |
| Kinaset Therapeutics | Kinaset Therapeutics is a therapeutics company that focuses on the advancement of novel drugs in areas of unmet medical needs. The company was founded in 2020 and is headquartered in Medfield, Massachusetts. | $103M | Series B | Jan 10, 2026 |  |
| FoRx Therapeutics | FoRx Therapeutics is a recently incorporated privately-held company aiming to develop first-in-class compounds for cancer treatment. FoRx focuses on drugging key molecular targets involved in DNA replication stress, as a new approach towards the development of targeted anticancer drugs. | $50M | Series A | Dec 18, 2025 |  |
| Xeltis | A clinical-stage medical device company, Xeltis has developed the most advanced polymer-based restorative devices for cardiovascular treatment. Xeltis’ restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and for coronary artery bypass graft (CABG) surgery and pulmonary heart valves, for whichclinical trials are ongoing. Xeltis was formed through the merger of two Dutch/Swiss university spin-offs. It currently has operations in The Netherlands and in the USA. Xeltis’ investors include venture capital funds EQT Life Sciences, Kurma Partners, VI Partners and Ysios Capital as well as a number of private investors. In 2021, Xeltis secured a €15 million financing from the European Investment Bank and a €15 million funding from the European Innovation Council Accelerator (EIC) set up by the European Commission. | $55.2M | Debt Financing | Dec 02, 2025 |  |
| Electra Therapeutics | Electra Therapeutics is a clinical stage biotechnology company developing therapies for cancer and other immunological diseases. | $183M | Series C | Oct 22, 2025 |  |

10 of 184 investments shown.

## Co-investors
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 28 deals together
- [Andera Partners](https://shizune.co/investors/profile/edmond-de-rothschild-investment-partners) — VC Fund, 20 deals together
- [Gimv](https://shizune.co/investors/profile/gimv) — VC Fund, 16 deals together
- [Novartis Venture Fund](https://shizune.co/investors/profile/novartis-venture-fund) — VC Fund, 15 deals together
- [BioMedPartners](https://shizune.co/investors/profile/biomedpartners) — VC Fund, 14 deals together
- [Inkef](https://shizune.co/investors/profile/inkef-capital) — VC Fund, 12 deals together

## Similar investors

### Similar industry
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund
- [Limburgse Reconversie Maatschappij](https://shizune.co/investors/profile/limburgse-reconversie-maatschappij) — VC Fund
- [Qbic Fund](https://shizune.co/investors/profile/qbic-fund) — VC Fund

## Featured in investor lists
- [Biotech Investors](https://shizune.co/investors/biotech-investors)
- [Biotech VC Funds](https://shizune.co/investors/biotech-vc-funds)
- [Biotechnology Investors](https://shizune.co/investors/biotechnology-investors)
- [Biotechnology VC Funds](https://shizune.co/investors/biotechnology-vc-funds)
- [Health Care Investors](https://shizune.co/investors/health-care-investors)
- [Health Care VC Funds](https://shizune.co/investors/health-care-vc-funds)

## FAQ

### What does EQT Life Sciences invest in?

EQT Life Sciences invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 184 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is EQT Life Sciences's check size?

EQT Life Sciences typically joins rounds of $7.3M–$78M at Series A, $12M–$110M at Series B and $12M–$165M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds EQT Life Sciences participates in.

### How do I contact EQT Life Sciences?

Public channels for EQT Life Sciences include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at EQT Life Sciences?

The team at EQT Life Sciences includes Christoph Broja (Partner), Fouad Azzam (General Partner) and Joachim Rothe (General Partner), among 12 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co